PegBio Co

PegBio Co FCF Growth

The Year-over-Year Free Cash Flow Growth of PegBio Co (2565.HK) as of Nov 18, 2026 is 15.69 %. In the previous year, Year-over-Year Free Cash Flow Growth was 21.11 % — a change of -25.66% (lower).

FCF Growth

15.69 %

YoY

-25.66%

Last updated:

Year-over-Year Free Cash Flow Growth of PegBio Co is 2025 15.69 % . Year-over-Year Free Cash Flow Growth of PegBio Co was 2024 21.11 % . It decreases by -25.66% lower compared to the previous year.

The PegBio Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2023
-33.98 CNY
Jan 1, 2024
21.11 CNY
Jan 1, 2025
15.69 CNY
The PegBio Co FCF Growth history
YEARFCF GrowthYoY
15.69 %-25.66%
21.11 %-162.12%
-33.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Year-over-Year Free Cash Flow Growth of PegBio Co is 15.69 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth PegBio Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — PegBio Co

All Key Metrics — PegBio Co